Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Mercer

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Kidney International Reports|May 14, 2023
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT StudyJonathan Barratt, Brad Rovin, Muh Geot Wong, et al.
Kidney International Reports|May 20, 2024
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX StudyHoward Trachtman, Jai Radhakrishnan, Michelle N Rheault, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2021
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysisLesley A Inker, Hiddo J L Heerspink, Hocine Tighiouart, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 2, 2016
Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysisLesley A Inker, Hasi Mondal, Tom Greene, et al.
The New England Journal of Medicine|November 3, 2023
Sparsentan versus Irbesartan in Focal Segmental GlomerulosclerosisMichelle N Rheault, Charles E Alpers, Jonathan Barratt, et al.
Lancet (London, England)|November 6, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Kidney International Reports|May 14, 2023
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT StudyJonathan Barratt, Brad Rovin, Muh Geot Wong, et al.
Kidney International Reports|May 20, 2024
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX StudyHoward Trachtman, Jai Radhakrishnan, Michelle N Rheault, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2021
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysisLesley A Inker, Hiddo J L Heerspink, Hocine Tighiouart, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 2, 2016
Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysisLesley A Inker, Hasi Mondal, Tom Greene, et al.
The New England Journal of Medicine|November 3, 2023
Sparsentan versus Irbesartan in Focal Segmental GlomerulosclerosisMichelle N Rheault, Charles E Alpers, Jonathan Barratt, et al.
Lancet (London, England)|November 6, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, et al.
Pageof 3